Alexandre Yazigi

We are pleased to announce that the European Society of Cardiology (ESC), together with the European Atherosclerosis Society (EAS), has published the 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias: https://lnkd.in/eyfVrsJS Since the publication of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular (CV) risk, there have been several randomized controlled trials that might change patient management ahead of the next scheduled full dyslipidaemia Guidelines. This 2025 Focused Update addresses changes in recommendations for the treatment of dyslipidaemias based on new evidence published up until March 31, 2025.

480

7 commentaires

🎉We’re thrilled to announce that last week, Dr. Francesco Traverso of CDC Habilita – I Cedri performed the first Arvis™ surgery in Europe🎉 Dr. Traverso successfully carried out a total knee arthroplasty, implanting a Physica LMC with the support of Arvis™ Augmented Reality Surgical Guidance. “I really enjoyed using Arvis™ for the surgery. From the start, I found it easy to use and cost efficient Technologie which can be especially helpful for less experienced surgeons or those performing a high volume of procedures.” Stated Dr. Traverso, “Our scrub nurses also appreciated how quickly it integrates with standard instrumentation, without the need for bulky equipment.” Arvis™, Enovis’ wearable and self-contained system, provides real-time, zero footprint surgical guidance. It received CE mark approval for hip and knee earlier this summer, with shoulder expected soon. 🥇This surgery marks a major milestone for Enovis, underscoring our commitment to advancing orthopedic innovation and empowering surgeons worldwide with smart, enabling technologies that enhance precision without adding complexity. Special thanks to Dr. Traverso and his team for pioneering this technology in Europe, and to our colleagues in Italy for their invaluable contribution to this success. 👉 If you’re an orthopedic surgeon and would like to learn more about Arvis™, visit our website. https://hubs.la/Q03KXlpf0 #Enovis #medtech #CreatingBetterTogether #Arvis™ #Innovation #AugmentedReality #Orthopaedics Habilita Robotics Healthcare

124

4 commentaires

Highlighting integrins from extracellular vesicles as key players in the tumor microenvironment and metastasis: in this review article, Corina Ciobanasu at Alexandru Ioan Cuza University and Christophe Le Clainche at Institut de Biologie Intégrative de la Cellule - I2BC - discussed recent advances on the role of extracellular vesicle integrins in tumor initiation, proliferation, migration, and invasion. Integrins, a diverse family of cell adhesion molecules, were shown to regulate essential processes such as tumor differentiation, migration, growth, and neovascularization. Tumor-derived exosomes, a subtype of EVs, were found to be enriched in integrins reflective of their parent cells 🔗 https://lnkd.in/eurzD8wT These exosomal integrins promoted extracellular matrix remodeling, immune evasion, and vascular changes, and were strongly associated with tumor progression and organ-specific metastasis. Beyond their mechanistic role, exosomal integrins demonstrated potential as diagnostic and prognostic biomarkers due to their tissue-specific expression profiles. They also emerged as attractive therapeutic targets for disrupting tumor–stroma interactions and limiting metastatic dissemination. Overall, this study highlighted exosomal integrins as critical mediators of cancer biology and promising tools for advancing diagnosis and treatment. #extracellularvesicles #exosomes #integrins #cellmigration #Vesiculab

41

3 commentaires

For International Physicians: New evidence highlights the efficacy of the #ShockwaveReducer in patients with refractory angina due to both CTO and non-CTO lesions. This recent analysis by Konigstein et al. (2025), published in Clinical Research in Cardiology, shows that the #ShockwaveReducer significantly improves angina symptoms in patients with refractory angina, both with and without chronic total occlusion. The figure below illustrates the shift in CCS angina class over 1 year following Shockwave Reducer implantation, among the entire population, 77% of patients had improvement of at least 1 CCS class following reducer implantation, and 42% reported improvement of ≥ 2 grades of CCS at 1 year. Additionally, meaningful improvements in exercise capacity and quality of life across both groups were associated with Reducer implantation. 👏 Congratulations to the authors Prof. maayan konigstein, A. Moroni, Stefan Verheye, Lior Zornitzki, MD., Ophir Freund, & Shmuel Banai for this important contribution to advancing therapies for refractory angina patients. Check the article here: Efficacy of coronary sinus reducer in patients with refractory angina and chronic total occlusion | Clinical Research in Cardiology link: https://lnkd.in/g_HnufYG  Learn more about the Shockwave Reducer on our website: https://lnkd.in/gEnvk-Va Important Safety Information: http://bit.ly/3iEq7fC  Caution: Investigational Device. Limited by U.S. and Canadian law to investigational use. The Reducer is commercially available in certain countries outside the U.S. and Canada. Please contact your local representative for specific country availability.

67